Antiplatelet and antithrombin strategies in acute coronary syndrome: State-of-the-art review

Current Cardiology Reviews

Volumn 8, Issue 3, 2012, Pages 239-249

  Showkathali, Refai ^a   Natarajan, Arun ^a  

^a Basildon Thurrock University Hospitals Foundation NHS Trust   (United Kingdom)

Author keywords

ACS; Acute coronary syndrome; Antiplatelet agents; Antithrombotic agents; Bivalirudin; Cangrelor; NSTEMI; STEMI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ATOPAXAR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CLOPIDOGREL; CLOPIDOGREL PLUS OMEPRAZOLE; ENOXAPARIN; EPTIFIBATIDE; ESOMEPRAZOLE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LAMIFIBAN; OMEPRAZOLE; PLACEBO; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; RETEPLASE; RIVAROXABAN; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ANTITHROMBINS; DRUG INTERACTIONS; FACTOR XA; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTON PUMP INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTOR, PAR-1;

EID: 84870277534     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340312803217193     Document Type: Article

References (83)

1. Monroe D M, Hoffman M, Roberts H R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22(9): 1381-9.
2. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82(1): 17-26.
3. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3(8): 1597-602.
4. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000; 60(2): 347-77.
5. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-39.
6. Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G, Fox K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.
7. Mehta S R, Yusuf S, Peters R J, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358(9281): 527-33.
8. Steinhubl S R, Berger P B, Mann J T, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288(19): 2411-20.
9. Chen Z M, Jiang L X, Chen Y P, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366(9497): 1607-21.
10. Sabatine M S, Cannon C P, Gibson C M, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352(12): 1179-89.
11. Schomig A. Ticagrelor--is there need for a new player in the antiplatelet- therapy field? N Engl J Med 2009; 361(11): 1108-11.
12. Serebruany V L, Steinhubl S R, Berger P B, Malinin A I, Bhatt D L, Topol E J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45(2): 246-51.
13. Ho P M, Maddox T M, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937-44.
14. Juurlink D N, Gomes T, Ko D T, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj 2009; 180(7): 713-8.
15. Gilard M, Arnaud B, Cornily J C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51(3): 256-60.
16. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101(4): 714-9.
17. Small D S, Farid N A, Payne C D, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48(4): 475-84.
18. Depta JP, Bhatt DL. Omeprazole and clopidogrel: Should clinicians be worried? Cleve Clin J Med 77(2): 113-6.
19. O'Donoghue M L, Braunwald E, Antman E M, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374(9694): 989-97.
20. Bhatt D L, Cryer B L, Contant C F, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2011; 363(20): 1909-17.
21. Interaction between clopidogrel and proton-pump inhibitors. CHMP updates warning for clopidogrel-containing medicines. 2010 [cited 2010 Mar 17; Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/17494810en.pdf. (last accessed on 28 April 2012)
22. Jernberg T, Payne C D, Winters K J, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of nonresponders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27(10): 1166-73.
23. Wiviott S D, Trenk D, Frelinger A L, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116(25): 2923-32.
24. Brandt J T, Payne C D, Wiviott S D, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153(1): 66 e9-16.
25. Wiviott S D, Braunwald E, McCabe C H, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001-15.
26. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. [NICE guidance, UK] 2009 [cited 2009 NICE technology appraisal guidance 182; Available from: http://www.nice.org.uk/nicemedia/live/12324/45849/45849.pdf. (last accessed on 28 April 2012)
27. Storey R F, Husted S, Harrington R A, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50(19): 1852-6.
28. Husted S, Emanuelsson H, Heptinstall S, Sandset P M, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27(9): 1038-47.
29. Wallentin L, Becker R C, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045-57.
30. Boersma E, Harrington R A, Moliterno D J, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials. Lancet 2002; 359(9302): 189-98.
31. Ohman E M, Roe M T. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105(5): 763-5.
32. Serebruany V L. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105(5): 752-9.
33. Cannon C P, Husted S, Harrington R A, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50(19): 1844-51.
34. Wallentin L, Becker R C, James S K, Harrington R A. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified (Thromb Haemost 2011; 105.5). Thromb Haemost 2011; 105(5): 760-2.
35. Ticagrelor for the treatment of acute coronary syndromes. [NICE guidance, UK] Oct 2011 [cited 2011 Oct; NICE technology appraisal guidance 236; Available from: http://www.nice.org.uk/nicemedia/live/13588/56819/56819.pdf. (last accessed on 28 April 2012)
36. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31(20): 2501-55.
37. Storey R F, Sanderson H M, White A E, May J A, Cameron K E, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110(4): 925-34.
38. Storey R F, Wilcox R G, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13(7): 407-13.
39. Behan M W, Fox S C, Heptinstall S, Storey R F. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005; 16(2): 73-80.
40. Bhatt D L, Lincoff A M, Gibson C M, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361(24): 2330-41.
41. Harrington R A, Stone G W, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361(24): 2318-29.
42. Kastrati A, Ndrepepa G. Cangrelor - a champion lost in translation? N Engl J Med 2009; 361(24): 2382-4.
43. Angiolillo D J, Firstenberg M S, Price M J, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307(3): 265-74.
44. Leger A J, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114(10): 1070-7.
45. Chackalamannil S. Thrombin receptor (protease activated receptor- 1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 2006; 49(18): 5389-403.
46. Chackalamannil S, Xia Y, Greenlee W J, et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 2005; 48(19): 5884-7.
47. Serebruany V L, Kogushi M, Dastros-Pitei D, Flather M, Bhatt D L. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009; 102(1): 111-9.
48. Becker R C, Moliterno D J, Jennings L K, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebocontrolled phase II study. Lancet 2009; 373(9667): 919-28.
49. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR- 1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010; 17(2): 156-64.
50. O'Donoghue M L, Bhatt D L, Wiviott S D, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011; 123(17): 1843-53.
51. Wiviott S D, Flather M D, O'Donoghue M L, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011; 123(17): 1854-63.
52. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366(1): 20-33.
53. Morrow D A, Braunwald E, Bonaca M P, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366(15): 1404-13.
54. Hynes R O. Integrins: a family of cell surface receptors. Cell 1987; 48(4): 549-54.
55. Lefkovits J, Plow E F, Topol E J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332(23): 1553-9.
56. Chen P, Sun C, XLiu J N. A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin alpha IIb beta3 inhibits platelet aggregation and adhesion. J Biol Chem 2005; 280(27): 25403-8.
57. Coller B S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86(1): 427-43.
58. Topol E J, Ferguson J J, Weisman H F, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278(6): 479-84.
59. Topol E J, Lincoff A M, Kereiakes D J, et al. Multi-year followup of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113(1): 1-6.
60. Topol E J, Byzova T V, Plow E F. Platelet GPIIb-IIIa blockers. Lancet 1999; 353(9148): 227-31.
61. EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352(9122): 87-92.
62. Simoons M L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357(9272): 1915-24.
63. De Luca G, Suryapranata H, Stone G W, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293(14): 1759-65.
64. Kandzari D E, Hasselblad V, Tcheng J E, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004; 147(3): 457-62.
65. Brener S J, Barr L A, Burchenal J E, et al. Randomized, placebocontrolled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98(8): 734-41.
66. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344(25): 1895-903.
67. Boersma E, Akkerhuis K M, Theroux P, Califf R M, Topol E J, Simoons M L. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100(20): 2045-8.
68. Ellis S G, Tendera M, de Belder M A, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358(21): 2205-17.
69. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009; 119(14): 1933-40.
70. Thiele H, Wohrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 2012; 379(9819): 923-31.
71. Becker R C. Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. Am Heart J 2005; 149(1 Suppl): S2-8.
72. Ashby CR D J, Kunapuli SP, Smith JB. Platelet stimulatory and inhibitory receptors. in: R.W. Colman, Editor. Hemostasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins 2001; pp. 505-520.
73. Weitz J I, Bates E R. Direct thrombin inhibitors in cardiac disease. Cardiovasc Toxicol 2003; 3(1): 13-25.
74. Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol 2003; 41(4 Suppl S): 70S-78S.
75. Maraganore J M, Adelman B A. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 1996; 7(6): 438-48.
76. Stone G W, McLaurin B T, Cox D A, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355(21): 2203-16.
77. Stone G W, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358(21): 2218-30.
78. Stone G W, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377(9784): 2193-204.
79. Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 Suppl 1: 12-20.
80. Yusuf S, Mehta S R, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354(14): 1464-76.
81. Yusuf S, Mehta S R, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295(13): 1519-30.
82. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.
83. Alexander JH, Lopez RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365(8): 699-708.